powered by LeadingAge New York
  1. Home
  2. » Topics
  3. » Coronavirus Resources
  4. » Therapeutics Information
  5. » FDA/NIH Guidance

FDA/NIH Guidance

November 10, 2022

FDA/NIH Guidance

The COVID-19 Treatment Guidelines Panel’s Statement on Omicron Subvariants, Pre-Exposure Prophylaxis, and Therapeutic Management of Nonhospitalized Patients With COVID-19
Read More
October 25, 2022

FDA/NIH Guidance

EVUSHELD COVID-19 Treatment Available for Moderately to Severely Immunocompromised Individuals

The monoclonal antibody treatment is authorized as pre-exposure prophylaxis to prevent COVID-19.

Read More
September 26, 2022

FDA/NIH Guidance

NIH Guidance on Therapeutic Management of Nonhospitalized Adults With COVID-19
Read More
May 4, 2022

FDA/NIH Guidance

FDA Updates on Paxlovid for Health Care Providers
Read More
May 4, 2022

FDA/NIH Guidance

Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers
Read More
December 28, 2021

FDA/NIH Guidance

FDA Approves New Pill Form Antivirals for COVID-19

HHS pauses monoclonal antibody medications unlikely to work against Omicron variant.

Read More